申请人:Chugai Seiyaku Kabushiki Kaisha
公开号:US05574178A1
公开(公告)日:1996-11-12
Compounds represented by the general formula as well as intermediates for the synthesis of thereof: ##STR1## where R.sup.1 is a hydrogen atom or an acyl group; R.sup.2 is a lower alkyl group; R.sup.3 is a hydrogen atom or a lower alkyl group; R.sup.4, R.sup.5 and R.sup.6, which may be the same or different, are a hydrogen atom or an optionally substituted alkyl, alkenyl, alkynyl or aryl group; R.sup.2 and R.sup.4, when taken together, may form a 5-membered ring; R.sup.5 and R.sup.6, when taken together, may form a cycloalkyl group or a heterocyclic group in which at least one methylene on the ring of a cycloalkyl group is substituted by an oxygen atom, a sulfur atom or an alkyl-substituted nitrogen atom, provided that R.sup.6 is not present if the ring formed by R.sup.2 and R.sup.4 taken together is a benzofuran ring. The compounds represented by the general formula (I) have a highly selective anti-oxidative activity and are useful as therapeutics of ischemic diseases such as arteriosclerosis and myocardial infarction.
通式表示的化合物以及其合成的中间体:##STR1##其中R.sup.1是氢原子或酰基;R.sup.2是较低的烷基;R.sup.3是氢原子或较低的烷基;R.sup.4、R.sup.5和R.sup.6,可以相同也可以不同,是氢原子或可选择取代的烷基、烯基、炔基或芳基;当R.sup.2和R.sup.4一起时,可以形成一个5-成员环;当R.sup.5和R.sup.6一起时,可以形成一个环烷基或一个杂环基,其中环烷基的环上至少有一个甲基被氧原子、硫原子或烷基取代的氮原子取代,前提是如果由R.sup.2和R.sup.4一起形成的环是苯并呋喃环,则R.sup.6不存在。通式(I)表示的化合物具有高度选择性的抗氧化活性,并且可用作治疗缺血性疾病,如动脉粥样硬化和心肌梗死的药物。